Hey Pharmatech AI team,
Great ANN—thanks for sharing the details. After reading through, what stands out most to me is the revenue-sharing model for $PCH stakers (70% of fees in stablecoins) combined with the buyback & burn mechanism. It's a smart way to align token holders with real biotech revenue, especially targeting high-value markets like pain therapy and nanomedicine. The $5M from Rollman Management adds serious credibility, and the QuantifAI partnership for quant-trading integration? That's innovative for a pharma RWA play.

"Hi team,
Just dove into the Pharmatech AI thread and I'm genuinely impressed. What I like most is your AI-MDIP model—using Graph Neural Networks and Transformers for predicting drug interactions sounds like a game-changer for speeding up cannabinoid-based therapies. The fact that it's backed by your own proprietary cannabis data from the MDIP Lab Grow (50k+ data points per cycle!) gives it a real edge over generic AI tools. Plus, the sustainable 60-hectare solar-powered campus in Germany? That's forward-thinking for biotech.
Excited to see the pre-sale progress and upcoming SaaS launch in Q2 2025. Will keep an eye on this—rooting for those $100M+ licensing deals by 2027!
Best,
[My Bitcointalk Username= Emerison]